Jatin Shah's most recent trade in Karyopharm Therapeutics Inc was a trade of 1,306 Common Stock done at an average price of $12.1 . Disclosure was reported to the exchange on Feb. 17, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc | Jatin Shah | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.12 per share. | 17 Feb 2022 | 1,306 | 129,450 (0%) | 0% | 12.1 | 15,833 | Common Stock |
| Karyopharm Therapeutics Inc | Jatin Shah | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 9.86 per share. | 07 Feb 2022 | 1,704 | 130,756 (0%) | 0% | 9.9 | 16,805 | Common Stock |
| Karyopharm Therapeutics Inc | Jatin Shah | EVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.73 per share. | 12 Jul 2021 | 665 | 131,137 (0%) | 0% | 9.7 | 6,470 | Common Stock |
| Karyopharm Therapeutics Inc | Jatin Shah | EVP, Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 8.60 per share. | 07 May 2021 | 23,250 | 131,802 (0%) | 0% | 8.6 | 199,992 | Common Stock |
| Karyopharm Therapeutics Inc | Jatin Shah | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 59,968 | 59,968 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Jatin Shah | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 22,013 | 107,691 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Jatin Shah | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.83 per share. | 18 Feb 2021 | 1,186 | 51,791 (0%) | 0% | 14.8 | 17,590 | Common Stock |
| Karyopharm Therapeutics Inc | Jatin Shah | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2021 | 4,850 | 9,700 | - | - | Restricted Stock Units | |
| Karyopharm Therapeutics Inc | Jatin Shah | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2021 | 4,850 | 52,977 (0%) | 0% | - | Common Stock | |
| Karyopharm Therapeutics Inc | Jatin Shah | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.52 per share. | 11 Feb 2021 | 1,748 | 48,127 (0%) | 0% | 15.5 | 27,127 | Common Stock |
| Karyopharm Therapeutics Inc | Jatin Shah | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 5,650 | 49,875 (0%) | 0% | - | Common Stock | |
| Karyopharm Therapeutics Inc | Jatin Shah | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 5,650 | 16,950 | - | - | Restricted Stock Units |